| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
|
Lancet
|
2012
|
5.62
|
|
2
|
Gastrointestinal stromal tumours: origin and molecular oncology.
|
Nat Rev Cancer
|
2011
|
3.55
|
|
3
|
A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.
|
Clin Cancer Res
|
2012
|
2.78
|
|
4
|
Prevention and management of adverse events related to regorafenib.
|
Support Care Cancer
|
2013
|
1.00
|
|
5
|
Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists.
|
Target Oncol
|
2014
|
0.83
|
|
6
|
Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.
|
Int J Clin Oncol
|
2015
|
0.83
|
|
7
|
Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo.
|
Gastric Cancer
|
2014
|
0.82
|